VERA Stock Jumps 16% Premarket — Trutakna Cuts Kidney Disease Progression Risk By 76%, Full FDA Filing Planned In Q4
Vera Therapeutics Inc. (VERA) shares surged in Tuesday’s premarket trading after the company reported positive final Phase 3 results for Trutakna in adults with IgA nephropathy.Trutakna is Vera’s treatment for IgA nephropathy, a progressive kidney disease that can lead to kidney failure. Vera said…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.